83 results about "Truncated protein" patented technology

The invention discloses a recombinant VI-type collagen with antioxidant activity and application thereof, the recombinant VI-type collagen is a truncated protein of human VI-type collagen, and the amino acid sequence of the recombinant VI-type collagen is as shown in SEQ ID NO: 1. The recombinant type VI collagen can be expressed in an escherichia coli expression system, the expression yield is high, the tested biological activity (antioxidant activity, cell proliferation promoting activity and cell adhesion promoting activity) is obviously superior to that of natural type VI collagen, and the recombinant type VI collagen has excellent antioxidant activity, is an effective free radical scavenger, and can be used for preparing a biological preparation. The polypeptide can remove free radicals in the body, provides a molecular basis for some important physiological and pathological processes related to oxidation resistance, can be widely applied to the fields of food, health food, biological medicine and the like, and has good development and application prospects.

The invention discloses a recombinant human IV type collagen as well as a production method and application thereof. The amino acid sequence of the recombinant human IV type collagen is shown as SEQ ID No: 1. The recombinant human IV-type collagen is a truncated protein of a human IV-type collagen alpha1 chain, special expression elements and means are not needed, the yield of the recombinant human IV-type collagen can reach up to 18g / L only through extracellular secretory expression of a commercial pichia pastoris expression system, the yield is obviously higher than the high yield level of the recombinant collagen considered in the technical field, and the recombinant human IV-type collagen can be used for preparing the recombinant human IV-type collagen. The total length of the alpha 1 chain of the human IV-type collagen or other truncated proteins is obviously higher than that of the human IV-type collagen. In addition, the safety and biological activity of the recombinant human IV-type collagen are superior to the full length of the alpha 1 chain of the human IV-type collagen.

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.

The invention discloses recombinant human XVII type collagen with a hemostasis function and application of the recombinant human XVII type collagen. The recombinant human XVII type collagen is a truncated protein of the human XVII type collagen, and the amino acid sequence of the recombinant human XVII type collagen is shown as SEQ ID NO: 1. The recombinant human XVII type collagen has efficient and rapid hemostatic performance, meanwhile, the recombinant collagen is easy to separate and purify, a pure product with the purity reaching 97% or above can be prepared through simple membrane separation and chromatographic separation, and the production process is easy to amplify. In the aspect of hemostasis performance, compared with commercially available products, the recombinant human XVII type collagen has the advantages that the hemostasis time is obviously shortened, and the hemostasis performance is obviously improved.

The invention discloses a recombinant IV-type collagen with anti-inflammatory activity and a preparation method and application thereof, the recombinant IV-type collagen is a truncated protein of natural human IV-type collagen, and the amino acid sequence of the recombinant IV-type collagen is shown as SEQ ID NO: 1. The recombinant IV-type collagen has a remarkable anti-inflammatory effect, can regulate inflammatory factors, relieve and improve inflammatory symptoms, has anti-inflammatory and soothing effects, and can be used as a biomedical material to be applied to preparation of skin care products, medicines or medical instruments with anti-inflammatory activity.

The invention relates to a corn ZmmtRF2a gene mutation marker, an identification primer and application of the corn ZmmtRF2a gene mutation marker in regulation and control of grain development. A natural grain mutant crk5 found in a corn field breeding line selection process is utilized, a target gene ZmmtRF2a causing crk5 grain mutation is obtained through phenotypic analysis, linkage analysis and map-based cloning technologies, the gene encodes a peptide chain release factor 2a for mitochondrial localization, the peptide chain release factor 2a affects the mitochondrial function, and the gene can be used for inducing the mutation of the crk5 grain. The development of corn embryos and endosperm and the accumulation of grain storage substances are regulated and controlled. In crk5, ZmmtRF2a lacks 5th to 7th exons, the encoded truncated protein does not have GGQ and SPF motifs, the motifs are crucial to release activity of RF, mitochondrial binding and termination codon recognition, technical support is provided for utilization of the gene, and a new way is opened up.

The invention relates to the field of biological medicine and aquatic products, and discloses a grass carp IFNf interferon and truncated protein and application thereof in virus resistance or bacterium resistance. The applicant discovers the new subtype IFNf of the grass carp interferon for the first time, the protein coded by the new gene has an efficient antiviral effect, and the derived peptide AMP-G2 of the grass carp interferon has broad-spectrum antibacterial activity. The sensitivity of the grass carp interferon IFNf to grass carp reovirus (GCRV) infection is higher than that of other interferon, and the grass carp interferon IFNf shows obvious antiviral activity on the cellular level and can be used for preparing antiviral drugs. The interferon-derived peptide provided by the invention is a host natural peptide, is small in molecular weight and simple to synthesize, has a remarkable bactericidal effect on various bacteria and fungi, and can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs.

The invention discloses a method for improving the heterologous soluble expression efficiency of cytochrome P450, which is characterized in that plasmids containing coding genes of fungus-derived cytochrome P450 truncated protein and plasmids containing molecular chaperones are jointly transferred into host bacteria to obtain recombinant genetically engineered bacteria for improving the heterologous soluble expression efficiency of cytochrome P450. Through host screening, molecular chaperonin and cytochrome P450 gene modification, the soluble expression efficiency of cytochrome P450 in Escherichia coli is improved, and the problems of poor protein solubility and low expression efficiency when CYP450 is expressed in Escherichia coli at present are solved.

The invention discloses preparation and application of pseudorabies virus circular RNA (Ribonucleic Acid). The circular RNA comprises a coding element for coding any one of gD protein, gB protein, gC protein and gK protein of the pseudorabies virus; preferably, the coding element encodes a pseudorabies virus gD protein. Further, the encoding element encodes gD wild-type protein, gD truncated protein, gD mutant protein and gD truncated mutant protein; preferred coding elements encode gD truncated plus muteins. Further, the encoding element encodes an optimized nucleotide sequence of pseudorabies virus gD truncated and mutant protein. Further, the circular RNA comprises an optimized translation initiation element. Researches show that the circular RNA provided by the invention can induce protein expression in an animal body, generate a high-level neutralizing antibody and successfully activate T cell immunity, especially CD8 + T cell immune response, and a basis is provided for preparing a circular mRNA vaccine for preventing and / or treating pseudorabies.

The invention discloses an mRNA (messenger ribonucleic acid) vaccine for preventing and / or treating pseudorabies and application of the mRNA vaccine. Codon optimization is performed on a gene sequence of a pseudorabies virus gD protein antigen to obtain an optimized gene sequence of the pseudorabies virus gD protein antigen; the pseudorabies virus truncated gD protein antigen is obtained by optimizing the sequence of the pseudorabies virus gD protein antigen, the gene sequence of the truncated gD protein antigen is subjected to codon optimization, and experiments show that the optimized pseudorabies virus truncated gD protein antigen has higher expression quantity; the sequence-optimized pseudorabies virus truncated gD protein is further prepared into an mRNA vaccine, and after the mRNA vaccine is used for immunizing mice and piglets, it is found that the mRNA vaccine of the sgD protein can play an immune protection role on the mice and the piglets, and the mRNA vaccine is obviously superior to commercially available pseudorabies inactivated vaccines.

The invention discloses expression preparation and application of a truncated mycoplasma hyopneumoniae P65 protein. An original protein sequence of the full-length mycoplasma hyopneumoniae P65 protein is a sequence 2 in a sequence table, a coding gene of the full-length mycoplasma hyopneumoniae P65 protein is a sequence 1 in the sequence table, a truncated protein sequence is a sequence 4 in the sequence table, and a coding gene of the full-length mycoplasma hyopneumoniae P65 protein is a sequence 3 in the sequence table. The invention relates to preparation and application of a truncated mycoplasma hyopneumoniae P65 protein, which comprises the following steps: 1) transforming competence of escherichia coli BL21 (DE3) by a recombinant vector for expressing full-length and truncated mycoplasma hyopneumoniae P65 recombinant protein to respectively obtain recombinant bacteria for expressing the full-length and truncated mycoplasma hyopneumoniae P65 recombinant protein; (2) carrying out induced expression on the recombinant bacteria, collecting thalli, crushing, and collecting supernatant; dissolving and renaturating the inclusion body protein; (4) purifying inclusion body protein and supernatant protein; and 5) application of the truncated mycoplasma hyopneumoniae P65 recombinant protein in vaccine and antibody detection. The truncated mycoplasma hyopneumoniae P65 protein is expressed by adopting an escherichia coli expression system, the protein expression quantity is large, the stability is extremely good, the purification method is simple, the production cost is greatly reduced, and the promotion of subsequent large-scale production and application is facilitated.

The application relates to the fields of biological medicine and aquaculture, and discloses a zebrafish IFNf interferon truncated protein and application thereof in antibiosis. The zebrafish interferon derivative peptide AMP-Z2 can specifically inhibit fungi. The interferon derivative peptide provided by the application is a host natural peptide, has small molecular weight, is simple to synthesize, has significant bactericidal effects on various bacteria and fungi, and can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs.

The application belongs to the technical field of bioengineering, and particularly relates to application of a riboflavin kinase / FMN adenosine transferase truncated protein and a mutant thereof in FMN synthesis. The application obtains a mutant with improved riboflavin kinase enzyme activity by truncating and mutating RibFM-1, and uses the mutant in FMN production. The FMN yield of the strain containing the truncated protein gene is increased by 49.14%, 33.97%, 43.58%, 22.42%, 76.31% and 113.70% respectively compared with the strain containing the non-truncated gene. It can be seen that the riboflavin kinase / FMN adenosine transferase can significantly improve the yield of FMN after being truncated or mutated, and has a wide application potential in FMN industrial production.

This patent application discloses a recombinant human type II collagen, its preparation method, and its uses. The recombinant human type II collagen of this patent application is a truncated protein of natural human type II collagen, and its amino acid sequence is shown in SEQ ID No: 1. The recombinant human type II collagen of this invention can be expressed in commercial expression systems such as the commercial Pichia pastoris expression system with high expression yields. Furthermore, its tested biological activities (promoting cell proliferation and wound healing) are significantly superior to those of natural human type II collagen, and also significantly superior to other stages of natural human type II collagen.

Disclosed are virus-inspired compositions and preparation methods thereof, where the compositions comprise mutant papillomavirus L1 proteins that spontaneously form capsid backbones and that are conjugated to a peptide comprising an epitope to form immune redirector capsids (IRCs). The epitopes on the peptides are designed to be recognized by a subject's immune system based on the subject's preexisting immune memory developed from the subject's past exposure to the epitope through infection or vaccination. The mutant papillomavirus L1 proteins possess three mutations including an amino-terminal truncation, a carboxy-terminal truncation, and a truncation at helix four. These mutations in the L1 protein yield capsomeres that are form non-canonical T=1 geometry capsid backbones. Disclosed are uses and methods of using the compositions in treating and / or preventing cancers in subjects in need thereof.

The invention provides a cell strain capable of secreting anti-swine erysipelothrix spaA protein and application of the cell strain, and belongs to the technical field of antibodies. According to the invention, swine erysipelothrix truncation SpaA protein (SpaA-N) is used as an immunizing antigen for screening hybridoma cell strains secreting monoclonal antibodies for the first time to obtain hybridoma cells, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.45348. The hybridoma cell not only can generate a monoclonal antibody with strong specific binding capacity with an immune antigen or swine erysipelothrix, but also has higher hereditary stability in the performance of secreting the monoclonal antibody. Meanwhile, the monoclonal antibody secreted by the hybridoma cell strain SpaA-21D can realize immunohistochemical detection and indirect ELISA detection of swine erysipelothrix, and has good detection specificity. Therefore, the hybridoma cell strain and the monoclonal antibody secreted by the hybridoma cell strain provide a new means for detection of swine erysipelothrix.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The invention provides an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) Nsp4 protein monoclonal antibody with an inhibition effect and application thereof, a hybridoma cell strain capable of stably secreting the anti-Nsp4 protein monoclonal antibody is prepared, and a new antigen epitope is identified in nsp4 through expressed overlapping truncated protein. Wherein the 123ITEAGELV130 identified by the monoclonal antibody 1C11 shows the potential of universally identifying different types of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus). Meanwhile, expression of Nsp4 protein can be detected in the early stage of PRRSV infection by utilizing the monoclonal antibody 1C11, the monoclonal antibody has a blocking effect on PRRSV positive serum, and it is found that the monoclonal antibody 1C11 can inhibit proliferation of PRRSV in vitro. Research results increase the understanding of PRRSV Nsp4 protein structure and antigen characteristics, and provide a basis for PRRSV early antigen detection.

To provide adeno-associated variants, formulations and methods for pulmonary delivery.SOLUTION: The present disclosure provides variant AAV capsid proteins that confer tropism for lung cells, as well as recombinant adeno-associated viruses comprising the variant AAVs and pharmaceutical compositions comprising the same, and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of lung disorders. (ii) nucleic acids comprising, from 5 ' to 3 ', (a) AAV2 terminal repeats, (b) a promoter, (c) a nucleotide sequence encoding a human cystic fibrosis transmembrane conductance regulator (CFTR) or a biologically active truncated CFTR lacking amino acids 708 to 759 of the human CFTR sequence, (d) a poly-adenylation sequence, and (e) AAV2 terminal repeats.SELECTED DRAWING: None

The invention discloses preparation and application of a circular RNA (Ribonucleic Acid) molecule of a foot and mouth disease virus. The circular RNA comprises a coding element for coding any one of foot and mouth disease virus VP1 protein and VP3 protein; preferably, the coding element encodes foot and mouth disease virus VP1 protein. Further, the coding element codes a VP1 wild type protein, a VP1 truncated protein, a VP1 mutant protein and a VP1 truncated mutant protein; preferably, the coding element encodes the VP1 truncated and mutant protein. Further, the encoding element encodes an optimized nucleotide sequence of foot-and-mouth disease virus VP1 truncated and mutant protein. Further, the circular RNA comprises an optimized translation initiation element. Researches show that the circular RNA provided by the invention can induce protein expression in an animal body, generate a high-level virus blocking antibody and successfully activate T cell immunity, especially CD8 + T cell immune response, and a basis is provided for preparing a circular mRNA vaccine for preventing and / or treating foot-and-mouth disease.

The invention belongs to the technical field of biology, and particularly relates to a bovine viral diarrhea virus NS2 truncated protein and application thereof in BVDV antibody detection. The invention firstly provides a truncated protein of a BVDV NS2 protein, the truncated protein is subjected to soluble expression after being fused with glutathione S transferase (GST) and horse radish peroxidase (HRP) respectively, has better reactogenicity with positive serum of a BVDV antibody, does not react with negative serum of the BVDV antibody, and can be used for detecting the BVDV antibody; secondly, a fusion protein of GST and the truncated protein is taken as a coating antigen, a fusion protein of HRP and the truncated protein is taken as a detection antigen, a double-antigen sandwich ELISA method for BVDV antibody detection is constructed, and the method has the technical advantages of high sensitivity, good specificity, simplicity and convenience in operation, easiness in popularization, low cost and the like, and can be applied to screening of BVDV antibodies in cattle.

The invention provides a preparation method and application of a siniperca chuatsi infectious spleen and kidney necrosis virus subunit vaccine. Immunogen of the siniperca chuatsi infectious spleen and kidney necrosis virus subunit vaccine comprises capsid protein MCP of infectious spleen and kidney necrosis virus, envelope protein ORF007L and truncated protein of envelope protein ORF118L; wherein the amino acid sequence of the truncated protein of the capsid protein MCP is as shown in SEQ ID NO. 1; a gene sequence for editing the truncated protein is as shown in SEQ ID NO.4; the amino acid sequence of the truncated protein of the envelope protein ORF007L is as shown in SEQ ID NO. 2; the gene sequence for editing the truncated protein is as shown in SEQ ID NO.5; the amino acid sequence of the truncated protein of the envelope protein ORF118L is as shown in SEQ ID NO. 3; and the gene sequence for editing the truncated protein is as shown in SEQ ID NO.6.

The invention relates to the technical field of biology, in particular to engineered nuclease and application thereof, and particularly, nuclease with small protein molecular weight is obtained by optimizing a Cas protein structural domain. Through modification and optimization of a Cas protein structural domain, it is found that the truncated protein composed of PI, REC-I and WED structural domains at the N end of the V-type Cas protein can give play to the activity of nuclease, and a new path and a new research direction are provided for development and application of nuclease.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

Methods and devices to capture and analyze aerosolized particles such as protein biomarkers and their truncated proteoforms characteristic of a disease, including a respiratory disease, in exhaled breath to enable rapid detection of diseases are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using one or more solvents and analyzed using devices including mass spectrometry.

The invention provides an IGF2BP3 truncated protein mutant, an overexpression vector and application of the IGF2BP3 truncated protein mutant and belongs to the technical field of genetic engineering, and the IGF2BP3 truncated protein mutant is any one of the following items: 1) a truncated protein mutant I obtained by truncating a KH1-4 structural domain on the basis of IGF2BP3 wild type protein; 2) a truncated protein mutant II obtained by truncating a KH1-2 structural domain on the basis of IGF2BP3 wild type protein; 3) a truncated protein mutant III obtained by truncating a KH3-4 structural domain on the basis of IGF2BP3 wild-type protein.According to the invention, the specific KH structural domain can be systematically disassembled and studied through the obtained different IGF2BP3 truncated protein mutants, and further understanding of the functional mechanism of IGF2BP3 is promoted.

Provided are modified proteins that are functional in RNA-guided DNA cleavage. The proteins include modified IscBs protein that have a modification of the N-terminus or C-terminus, or both. The modifications include a truncation of a PLMP domain of the IscB protein, or a PLMP domain that is relocated to a position of the IscB protein that is not the N-terminus. The modified IscB protein can be provided as a component of a fusion protein. The modified IscB proteins are used with an ωRNA to modify a DNA substrate.

The present invention discloses a bivalent subunit vaccine for porcine contagious pleuropneumonia and porcine pasteurellosis, belonging to the field of veterinary vaccines. The bivalent subunit vaccine of the present invention contains truncated porcine Actinobacillus pleuropneumoniae antigenic proteins ApxⅠAN, ApxⅡAN, ApxⅢAN and OmpD and porcine Pasteurella multocida antigenic proteins PlpE and VacJ, which can provide cross-protection to porcine contagious Actinobacillus pleuropneumoniae and porcine Pasteurella multocida of different serotypes. The truncated proteins selected in the antigen protein combination of the present invention can all be efficiently soluble and expressed, and are easy to mass produce with low cost. The present invention provides an effective technical means for the prevention and treatment of porcine contagious pleuropneumonia and porcine pasteurellosis.

The invention provides a PMFBP1 mutant gene related to azoospermia syndrome and an application of the PMFBP1 mutant gene. The mutant gene is a PMFBP1 gene c.2641Cgt; the protein p.Arg881Ter is subjected to non-sense mutation, so that the encoded protein p.Arg881Ter is truncated, and the function of a sperm head-tail connection device is damaged. The invention also provides a specific Sanger sequencing detection method and a kit of the mutation, which can be used for rapid molecular diagnosis, genetic counseling and assisted reproduction guidance of the disease, and provides a basis for precise medical treatment.

The invention discloses preparation and application of a rabies virus circular RNA (Ribonucleic Acid) molecule. The circular RNA comprises a coding element for coding rabies virus G protein. Further, the encoding element encodes a wild type G protein, a G truncated protein, a G mutant protein and a G truncated and mutant protein; preferred coding elements encode G truncated plus muteins. Further, the encoding element encodes an optimized nucleotide sequence of rabies virus G truncated plus mutant protein. Further, the circular RNA comprises an optimized translation initiation element. Research shows that the circular RNA provided by the invention can induce protein expression, a higher-level neutralizing antibody and a more lasting drug effect can be generated by only one-time administration in an animal body, and a basis is provided for preparing a circular mRNA vaccine for preventing and / or treating rabies.